FINWIRES · TerminalLIVE
FINWIRES

研究快讯:Run公司利润率强劲,但现金消耗令人失望

By

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师总结如下:RUN公布的第一季度销售额为7.22亿美元(同比增长43%),高于市场普遍预期的约6.39亿美元。但我们认为这主要是会计报表方面的问题,而非业务基本面的加速增长。运营指标显示,RUN的业务量显著下降,新增储能容量(282兆瓦时,同比下降15%)、太阳能发电容量(154兆瓦,同比下降19%)和新增用户数(17,665,同比下降25%)均出现下滑。我们认为RUN以储能为先的战略定位有利于其在分布式能源领域的长期发展,目前其储能接入率已达到创纪录的73%(同比增长400个基点),但储能的商业化仍处于早期阶段。尽管2026年第一季度现金消耗达5900万美元(而2025年第一季度为现金盈余5600万美元),管理层仍维持2026年2.5亿美元至4.5亿美元的现金流预期。我们认为,净用户价值提升至118.92亿美元(同比增长14%)令人鼓舞,这主要得益于系统规模扩大和资本成本降低,但更广泛的行业逆风因素正发挥着越来越重要的作用。

Related Articles

Asia

StarHub's Net Attributable Profit Falls 81% in Q1

StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.

$SGX:CC3
Asia

Meesho Narrows Consolidated Loss in Fiscal Q4

Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.

$BOM:544632$NSE:MEESHO
Asia

Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug

Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.

$SHE:000661